Stock Taper 
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company developing therapies like ALX148 for various cancers, with collaborations and licenses to advance cancer immunotherapy.
Evorpacept is a clinical-stage CD47 blocker designed to enhance immune detection of cancer cells, currently in trials for gastric, head and neck, and breast cancers.
ALX Oncology presented compelling results from a Phase 2 investigator-sponsored trial of its lead drug candidate, evorpacept, at the American Society of Hematology (ASH) Annual Meeting. The data showed that evorpacept, in combination with standard treatments, achieved a 92% complete response rate in patients with indolent B-cell non-Hodgkin lymphoma, a significant improvement over historical response rates.
In a significant strategic move to enhance operational efficiency and focus on its most promising clinical programs, ALX Oncology Holdings Inc. announced a company-wide restructuring that includes a workforce reduction of approximately 30%. This decision is intended to prioritize the company's clinical development pipeline and extend its cash runway.
Achieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for control, with response rates increasing to 63.6% versus 23.1% among patients with high CD47 expression and retained HER2-positive disease
Overall rating: C
| PEER | PRICE | |
|---|---|---|
 KYMR | $106.40 | COMPARE |
 STOK | $25.10 | COMPARE |
 GLUE | $10.38 | COMPARE |
 ANNX | $4.17 | COMPARE |
 BCYC | $3.98 | COMPARE |
 ARTV | $11.17 | COMPARE |
 STRO | $25.43 | COMPARE |
 IMUX | $15.19 | COMPARE |
